The importance of dose and schedule in cancer chemotherapy

Rc, Leonard

doi:10.1097/00001813-199510005-00003

Anti-Cancer Drugs

1995

DOI: 10.1097/00001813-199510005-00003

|View full text |Cite

The importance of dose and schedule in cancer chemotherapy

Leonard Rc

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2007

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area

Kaestner

Sewell

2007

Clinical Oncology

View full text Add to dashboard Cite

Cytotoxic chemotherapy is characterised by a low therapeutic index and significant variability in therapeutic and toxic effects. In an attempt to reduce this variability, most chemotherapy doses are individualised according to patient body surface area (BSA). This practice, which was introduced almost 50 years ago, clearly has practical and economic implications for the healthcare system. Furthermore, the clinical value of this approach has, in recent years, been questioned. Despite established practice, chemotherapy dose selection remains complicated, partly because treatment effects are difficult to measure, partly because drugs are used in combination with other treatment modalities, and also because the patient's condition may change with disease progression. Various patient-related factors can affect drug pharmacokinetics (PK) and pharmacodynamics (PD), for example organ function, expression and activity of metabolising enzymes, drug resistance, body size, gender, age, concomitant disease and co-administration of other drugs. These factors may be of clinical significance in chemotherapy dose determination and measures of PK, PD or both feature in attempts to devise more rigorous methods for chemotherapy dosing. Part I of this series of two reviews describes the history and clinical impact of BSA-based chemotherapy, and examines the scientific evidence to support BSA dosing. It evaluates the factors affecting PK and PD for specific drugs that could inform and refine dose determination.

show abstract

Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area

Kaestner

Sewell

2007

Clinical Oncology

View full text Add to dashboard Cite

show abstract

Intravesical Chemotherapy With Epirubicin: A Dose Response Study

Masters¹,

Popert

Thompson

et al. 1999

Journal of Urology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The importance of dose and schedule in cancer chemotherapy

Cited by 2 publications

References 0 publications

Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area

Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area

Intravesical Chemotherapy With Epirubicin: A Dose Response Study

Contact Info

Product

Resources

About